logo-loader
RNS
viewSynairgen PLC

Synairgen plc - Result of AGM

RNS Number : 4198R
Synairgen plc
29 June 2020
 

RNS

Press release

Synairgen plc

('Synairgen' or the 'Company')

 

Result of AGM

 

 

Southampton, UK - 29 June 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that all resolutions proposed at its Annual General Meeting, held earlier today, were duly passed.

 

The full results of the proxy voting can be found on the Company's website: https://www.synairgen.com/wp-content/uploads/2020/06/2020-AGM-proxy-vote-summary.pdf

 

 

-Ends-

 

 

For further enquiries, please contact:

 

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

 

finnCap

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

Tel: + 44 (0) 20 7220 0500

 

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Sue Stuart, Olivia Manser

[email protected]

Tel: +44 (0) 20 3709 5700

 

 

Notes for Editors

 

About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.  

 

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016). The 220 patient trial comprises 100 patients to be initiated in hospital and 120 patients to be initiated in the home setting. A successful outcome will inform onwards progression of SNG001 in COVID-19 patients. Results from the hospital setting are expected in July 2020.

 

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGBSGDLUBDDGGC

Quick facts: Synairgen PLC

Price: 218

Market: AIM
Market Cap: £325.76 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18